Tags

Type your tag names separated by a space and hit enter

CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.
World J Biol Psychiatry 2003; 4(4):147-55WJ

Abstract

Today we have the first therapeutic compounds for treatment of Alzheimer's disease (AD) e.g. acetylcholine esterase inhibitors and in the near future we may expect new compounds such as gamma- and beta-secretase inhibitors. This has demanded increased accuracy in the diagnosis of AD and thus, among other possible approaches, diagnostic markers in the cerebrospinal fluid (CSF) have become a rapidly growing research field. Especially early in the course of the disease, when correct diagnosis is most difficult, such biomarkers would be especially valuable as one might expect the compounds to have the greatest potential of being effective. Two of the defining lesions in AD brains are senile plaques and neurofibrillary tangles with beta-amyloid (Abeta) and tau proteins as the main components respectively. Abeta and tau proteins are secreted to body fluids including plasma and cerebrospinal fluid (CSF). In this paper we review CSF markers for AD, with focus on their role in the clinical diagnosis. Reduced CSF levels of the 42 amino acid form of Abeta (Abeta42) and increased CSF levels of total tau (T-tau) in AD have been found in numerous studies, with high sensitivity figures. However, the specificity against other dementias is lower. The addition of phospho-tau (P-tau) seems to increase the specificity, since normal levels are found in other dementias and in cerebrovascular disease. An increasing number of studies suggests that these CSF markers perform well enough to have a role in the clinical work-up of patients with dementia if used together. We stress that the CSF markers should be combined with the clinical information and brain-imaging techniques.

Authors+Show Affiliations

Karolinska Institute NEUROTEC, Neurotec, Huddinge University Hospital, Sweden. niels.andreasen@neurotec.ki.seNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14608585

Citation

Andreasen, Niels, et al. "CSF Markers for Alzheimer's Disease: Total Tau, Phospho-tau and Abeta42." The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, vol. 4, no. 4, 2003, pp. 147-55.
Andreasen N, Sjögren M, Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. World J Biol Psychiatry. 2003;4(4):147-55.
Andreasen, N., Sjögren, M., & Blennow, K. (2003). CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry, 4(4), pp. 147-55.
Andreasen N, Sjögren M, Blennow K. CSF Markers for Alzheimer's Disease: Total Tau, Phospho-tau and Abeta42. World J Biol Psychiatry. 2003;4(4):147-55. PubMed PMID: 14608585.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42. AU - Andreasen,Niels, AU - Sjögren,Magnus, AU - Blennow,Kaj, PY - 2003/11/11/pubmed PY - 2004/1/30/medline PY - 2003/11/11/entrez SP - 147 EP - 55 JF - The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry JO - World J. Biol. Psychiatry VL - 4 IS - 4 N2 - Today we have the first therapeutic compounds for treatment of Alzheimer's disease (AD) e.g. acetylcholine esterase inhibitors and in the near future we may expect new compounds such as gamma- and beta-secretase inhibitors. This has demanded increased accuracy in the diagnosis of AD and thus, among other possible approaches, diagnostic markers in the cerebrospinal fluid (CSF) have become a rapidly growing research field. Especially early in the course of the disease, when correct diagnosis is most difficult, such biomarkers would be especially valuable as one might expect the compounds to have the greatest potential of being effective. Two of the defining lesions in AD brains are senile plaques and neurofibrillary tangles with beta-amyloid (Abeta) and tau proteins as the main components respectively. Abeta and tau proteins are secreted to body fluids including plasma and cerebrospinal fluid (CSF). In this paper we review CSF markers for AD, with focus on their role in the clinical diagnosis. Reduced CSF levels of the 42 amino acid form of Abeta (Abeta42) and increased CSF levels of total tau (T-tau) in AD have been found in numerous studies, with high sensitivity figures. However, the specificity against other dementias is lower. The addition of phospho-tau (P-tau) seems to increase the specificity, since normal levels are found in other dementias and in cerebrovascular disease. An increasing number of studies suggests that these CSF markers perform well enough to have a role in the clinical work-up of patients with dementia if used together. We stress that the CSF markers should be combined with the clinical information and brain-imaging techniques. SN - 1562-2975 UR - https://www.unboundmedicine.com/medline/citation/14608585/CSF_markers_for_Alzheimer's_disease:_total_tau_phospho_tau_and_Abeta42_ L2 - https://medlineplus.gov/alzheimersdisease.html DB - PRIME DP - Unbound Medicine ER -